Companies work to develop combo mAb, NK cell COVID-19 therapy

By The Science Advisory Board staff writers

August 19, 2020 -- A new research project is bringing together universities and pharmaceutical companies to collaborate on the development of a combination of a monoclonal antibody (mAb) and natural killer (NK) cells as a treatment for COVID-19. The efforts are spearheaded by Harbour BioMed and expand on the company's work in using mAb against SARS-CoV-2.

Additional collaborators include Utrecht University, Erasmus Medical Center, Viroclinics, and Kiadis Pharma. The collaboration will explore the synergies between mAb and NK cells in eliminating SARS-CoV-2 and virally infected cells.

The new product will utilize Kiadis' K-NK cell therapy platform to address the severe lack of functional NK cells in COVID-19 patients. K-NK-Id101 cells potentially have antiviral activity without exacerbating inflammation. The cells can be manufactured at a large scale and frozen down for storage, making global distribution easier.

The fully human, nonblocking antibody, 49F1, targets a conserved region of the SARS-CoV-2 spike protein and binds to both SARS-CoV-2 and SARS-CoV in vitro.


Copyright © 2020 scienceboard.net
 
To access all The ScienceBoard content create a free account now:


Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.


Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Already have an account? Sign in here